Pharmacokinetics and bioequivalence study of valacyclovir hydrochloride capsules after single dose administration in healthy Chinese male volunteers

Abstract The aim of the present study was to compare the bioavailability of valacyclovir (CAS 124832-26-4; INN: valaciclovir) from two valacyclovir hydrochloride (CAS 214832-27-5) capsules (150 mg/capsule as test preparation and 150 mg/capsule commercially available original capsule of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 20 and 27. The study was conducted according to an open, randomized, single blind, 2-way crossover study design with a washout phase of 7 days. Blood samples for pharmacokinetic profiling were taken up to 24 h post-dose. Valacyclovir hydrochloride is rapidly converted to acyclovir (CAS 59277-89-3) after oral administration, so the pharmacokinetics and bioequivalence of valacyclovir hydrochloride can be studied by determining the plasma concentration of acyclovir. Plasma concentrations of acyclovir were determined with a validated liquid chromatographytandem mass spectrometry (LC-MS/MS) method. The pharmacokinetic parameters of test and reference formulations were estimated as follows: the maximum plasma concentrations (Cmax) were 2.04 ± 0.43 μg/mL and 2.01 ± 0.50 μg/mL; the median Tmax were 1.1 ± 0.3 h and 1.0 ± 0.3 h; plasma elimination half-lives (t1/2) were 2.94 ± 0.42 h and 2.85 ± 0.28 h. Values of AUC0–t demonstrate nearly identical bioavailability of valacyclovir hydrochloride from the examined formulations. AUC0–15 were 6.70 ± 1.26 μg · h/mL and 6.96 ± 1.25 μg · h/mL. Areas under the plasma concentration-time curve (AUC0–∞ were 6.90 ± 1.30 μg · h/mL and 7.15 ± 1.31 μg · h/mL. Both primary target parameters, AUC0–∞ and AUC0–t were tested parametrically by analysis of variance (ANOVA) and relative bioavailabilities were 96.69 ± 7.89% for AUC0–∞, 96.40 ±8.0% for AUC0–15. Bioequivalence between test and reference preparation was demonstrated for both parameters, AUC0–∞ and AUC0–t. The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80–125%. It meant that the test formulation was bioequivalent to the reference formulation for valacyclovir hydrochloride.

[1]  H. Nauwynck,et al.  Pharmacokinetics of Acyclovir after Intravenous Infusion of Acyclovir and after Oral Administration of Acyclovir and Its Prodrug Valacyclovir in Healthy Adult Horses , 2007, Antimicrobial Agents and Chemotherapy.

[2]  A. S. Jadhav,et al.  Development and validation of enantioselective high performance liquid chromatographic method for Valacyclovir, an antiviral drug in drug substance. , 2007, Journal of pharmaceutical and biomedical analysis.

[3]  G. Amidon,et al.  Gene Expression in the Human Intestine and Correlation with Oral Valacyclovir Pharmacokinetic Parameters , 2003, Journal of Pharmacology and Experimental Therapeutics.

[4]  W. Sadee,et al.  Intra- and Interindividual Variabilities of Valacyclovir Oral Bioavailability and Effect of Coadministration of an hPEPT1 Inhibitor , 2003, Antimicrobial Agents and Chemotherapy.

[5]  S. Eksborg,et al.  Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? , 2002, Medical and pediatric oncology.

[6]  C. Perry,et al.  Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. , 1996, Drugs.

[7]  P. Rolan,et al.  Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans , 1995, Antimicrobial agents and chemotherapy.

[8]  K. Beutner,et al.  Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. , 1995, Antiviral research.

[9]  M. Jacobson,et al.  Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease , 1994, Antimicrobial Agents and Chemotherapy.

[10]  F. Mandelli,et al.  Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation , 1994, The Lancet.

[11]  D. Cederberg,et al.  Pharmacokinetics of the acyclovir pro‐drug valaciclovir after escalating single‐and multiple‐dose administration to normal volunteers , 1993, Clinical pharmacology and therapeutics.

[12]  D. Campoli-Richards,et al.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. , 1989, Drugs.

[13]  H. Itoh,et al.  Influence of ALDH2 genetic polymorphisms on aciclovir pharmacokinetics following oral administration of valaciclovir in Japanese end-stage renal disease patients. , 2008, Drug metabolism and pharmacokinetics.

[14]  T. Spector,et al.  Acyclovir: mechanism of antiviral action and potentiation by ribonucleotide reductase inhibitors. , 1991, Advances in pharmacology.

[15]  V. Steinijans,et al.  Striving for standards in bioequivalence assessment: a review. , 1991, International journal of clinical pharmacology, therapy, and toxicology.